CD8A and myeloid sarcoma: Overall, our work shows a systematic analysis of circulating CD161highVα7.2+CD8+ MAIT cells at distinct courses of MS and in ALS, and demonstrates that the drop of CD8+ MAIT cells, also in the respective TEM and TCM subpopulations, represents an immunological feature emerging in primary progressive disease.